Market Overview

Afternoon Market Gainers

Related BLUE
Why Drug Pricing Could Bring Volatility To The Biotech Sector This Year
10 Biotech Stories You Might've Missed This Week
Related NKTR
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts

Bluebird Bio (NASDAQ: BLUE) traded up 49.55 percent to $25.41. Wednesday's IPO for the company was initially priced at $17.

Nektar Therapeutics (NASDAQ: NKTR) rose 9.99 percent to $10.79 after announcing positive top-line results from a human abuse liability (HAL) study for NKTR-181.

Gevo (NASDAQ: GEVO) climbed 9.23 percent to $2.26 after yesterday's announcement that it had resumed commercial production of Isobutanol.

Keryx BioPharma (NASDAQ: KERX) shot up 6.50 percent to $8.16 after analysts at JP Morgan initiated coverage on the stock with an Overweight rating.

MannKind (NASDAQ: MNKD) regained 6.48 percent to $7.03 after yesterday's double-digit drop.

Posted-In: News Movers


Related Articles (GEVO + BLUE)

Around the Web, We're Loving...

Get Benzinga's Newsletters